AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at ...

Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA delivery platforms, for up to $2. ...

LSEG also reported a 78% increase in deals worth more than $10 billion during the first half of 2025, compared to 2024 levels ...

Perhaps shortly after this came the sales forecasts, which at the time were in the region of $5 billion per year at peak. It wasn’t a Humira, but AbbVie was realistic enough to accept that it ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...